Springhill Fund Asset Management HK Co Ltd Makes New Investment in Janux Therapeutics, Inc. (NASDAQ:JANX)

Springhill Fund Asset Management HK Co Ltd acquired a new stake in Janux Therapeutics, Inc. (NASDAQ:JANX) during the fourth quarter, HoldingsChannel reports. The firm acquired 29,600 shares of the company’s stock, valued at approximately $1,585,000. Janux Therapeutics comprises about 2.6% of Springhill Fund Asset Management HK Co Ltd’s investment portfolio, making the stock its 15th largest holding.

Several other institutional investors have also recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. grew its stake in Janux Therapeutics by 202.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company’s stock worth $10,639,000 after buying an additional 156,675 shares during the last quarter. Lester Murray Antman dba SimplyRich grew its position in shares of Janux Therapeutics by 205.3% during the fourth quarter. Lester Murray Antman dba SimplyRich now owns 24,315 shares of the company’s stock worth $1,301,000 after acquiring an additional 16,351 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Janux Therapeutics by 6.2% in the 3rd quarter. Geode Capital Management LLC now owns 662,594 shares of the company’s stock valued at $30,107,000 after acquiring an additional 38,490 shares during the period. Neo Ivy Capital Management purchased a new stake in Janux Therapeutics in the 3rd quarter valued at $940,000. Finally, abrdn plc acquired a new stake in Janux Therapeutics during the 4th quarter worth $3,430,000. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Insider Buying and Selling at Janux Therapeutics

In related news, insider Andrew Hollman Meyer sold 3,334 shares of the business’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $32.15, for a total value of $107,188.10. Following the sale, the insider now directly owns 82,139 shares in the company, valued at $2,640,768.85. The trade was a 3.90 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ra Capital Management, L.P. acquired 341,742 shares of the stock in a transaction that occurred on Wednesday, March 5th. The stock was acquired at an average cost of $30.64 per share, for a total transaction of $10,470,974.88. Following the completion of the purchase, the director now owns 9,658,988 shares in the company, valued at $295,951,392.32. The trade was a 3.67 % increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders sold 11,668 shares of company stock valued at $548,183. Corporate insiders own 29.40% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. Lifesci Capital upgraded shares of Janux Therapeutics to a “strong-buy” rating in a research note on Friday, December 27th. William Blair restated an “outperform” rating on shares of Janux Therapeutics in a research report on Friday, January 10th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $200.00 price objective on shares of Janux Therapeutics in a research report on Wednesday, December 11th. Scotiabank dropped their target price on Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating on the stock in a report on Friday, February 28th. Finally, Wedbush reaffirmed an “outperform” rating and set a $76.00 price target (up from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. One investment analyst has rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, Janux Therapeutics currently has a consensus rating of “Buy” and an average target price of $92.44.

Janux Therapeutics Stock Performance

Janux Therapeutics stock opened at $25.77 on Friday. The company has a market cap of $1.52 billion, a P/E ratio of -22.03 and a beta of 3.27. Janux Therapeutics, Inc. has a one year low of $24.30 and a one year high of $71.71. The business has a fifty day moving average of $34.09 and a two-hundred day moving average of $45.26.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. Sell-side analysts predict that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.